DEC. 17–LAS VEGAS–Skinvisible, Inc. through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc. says its patented antimicrobial hand sanitizer demonstrated a greater than 99% kill in laboratory studies against the Influenza A virus.
“Our studies performed at an FDA compliant laboratory confirm that our antimicrobial hand sanitizer product may help in preventing the spread of the Influenza A virus caused from hand to hand and surface to hand contact,” says Skinvisible’s CEO Terry Howlett.
Manufactured for and marketed by Michigan based Dermal Defense, Inc., this antimicrobial hand sanitizer incorporates Skinvisible’s proprietary Invisicare polymer delivery system. Notable, proven advantages of the formulation include its ability to adhere to the skin, thereby forming a protective bond. It resists both wash-off and perspiration while holding the active ingredient Triclosan on the skin for extended periods of time.
The product, marketed as Dermal Defense offers the added advantage of being alcohol-free.